Table 2.
Univariate and multivariate Cox regression analyses of potential factors affecting PFS in Chinese OC cohort.
| Univariate analysis | Multivariate analysis | |||||
| Parameter | HR | 95% CI | P | HR | 95% CI | P |
| Age | 1.038 | 1.008–1.069 | .013 | 1.031 | 0.995–1.069 | .095 |
| Weight | 1.007 | 0.959–1.057 | .787 | |||
| ECOG | 3.357 | 1.448–7.784 | .005 | 2.243 | 0.833–6.038 | .11 |
| Pathology | 0.994 | 0.547–1.806 | .983 | |||
| TNM stage | 1.184 | 0.658–2.130 | .573 | |||
| Seroperitoneum | 2.333 | 0.961–5.661 | .061 | |||
| Implanting metastasis of peritoneum | 0.708 | 0.358–1.401 | .322 | |||
| Liver metastasis | 0.641 | 0.338–1.216 | .174 | |||
| Lung metastasis | 1.61 | 0.853–3.039 | .142 | |||
| Bone metastasis | 3.354 | 1.149–9.795 | .027 | 4.215 | 1.351–13.148 | .013 |
| Metastasis sites | 1.006 | 0.836–1.211 | .946 | |||
| Prior system therapy lines | 1.085 | 0.593–1.986 | .791 | |||
| Chemotherapy(platinum based and non-platinum based) | 0.655 | 0.379–1.130 | .129 | |||
| TP53 | 1.554 | 0.725–3.331 | .257 | |||
| EGFR | 2.953 | 1.193–7.309 | .019 | 6.392 | 2.254–18.128 | <.001 |
| KRAS | 0.78 | 0.302–2.014 | .608 | |||
| HER2 | 2.663 | 1.024–6.923 | .045 | 3. 577 | 1.269–10.080 | .016 |
| PIK3CA | 1.603 | 0.760–3.381 | .215 | |||
| MET | 1.775 | 0.627–5.029 | .28 | |||
| MYC | 0.235 | 0.056–0.991 | .049 | 0.214 | 0.045–1.015 | .052 |
| CDKN2A | 1.056 | 0.251–4.443 | .94 | |||
CI = confidence interval, ECOG = The Eastern Cooperative Oncology Group, HR = hazard ratio, OC = ovarian cancer, P = probability, TNM = The Tumor, Node, Metastasis staging system.